quinolinic acid has been researched along with levodopa in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (27.27) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Beskid, M; Finkiewicz-Murawiejska, L | 1 |
| Di Chiara, G; Fenu, S; Morelli, M; Pinna, A | 1 |
| Honey, CR; Shen, H | 1 |
| Rassoulpour, A; Schwarcz, R; Wu, HQ | 1 |
| Bédard, PJ; Grégoire, L; Guidetti, P; Izzo, E; Rassoulpour, A; Samadi, P; Schwarcz, R | 1 |
| Bédard, PJ; Di Paolo, T; Grégoire, L; Guidetti, P; Izzo, E; Rassoulpour, A; Samadi, P; Schwarcz, R | 1 |
| Gago, B; Marin, C; Obeso, JA; Rodríguez-Oroz, MC | 1 |
| Jeon, SR; Kim, YH; Shin, ES; Yoon, HH | 1 |
| Döbrössy, M; Garcia, J; Göbel, G; Granata, R; Jellinger, K; Kaindlstorfer, C; Krismer, F; Stefanova, N; Wenning, GK | 1 |
| Asakawa, T; Chen, W; Jia, X; Qin, W; Shi, Y | 1 |
1 review(s) available for quinolinic acid and levodopa
| Article | Year |
|---|---|
Can kynurenine pathway be considered as a next-generation therapeutic target for Parkinson's disease? An update information.
Topics: 3-Hydroxyanthranilic Acid; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Levodopa; Parkinson Disease; Quinolinic Acid; Tryptophan | 2022 |
10 other study(ies) available for quinolinic acid and levodopa
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Quinolinic acid: effects on brain catecholamine and c-AMP content during L-dopa and reserpine administration.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Brain; Catecholamines; Cyclic AMP; Dopamine; Epinephrine; Levodopa; Male; Norepinephrine; Quinolinic Acid; Quinolinic Acids; Rats; Reserpine | 1992 |
Adenosine A2 receptors interact negatively with dopamine D1 and D2 receptors in unilaterally 6-hydroxydopamine-lesioned rats.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adenosine; Animals; Antihypertensive Agents; Autoradiography; Basal Ganglia; Benserazide; Binding Sites; Dopamine Agents; Ergolines; Levodopa; Male; Neural Pathways; Neurons; Oxidopamine; Phenethylamines; Quinolinic Acid; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Purinergic P1; Stereotyped Behavior | 1994 |
Circling behaviour in 6-hydroxydopamine-lesioned rats given pulsed levodopa is reduced more by lesions in the entopeduncular nucleus/substantia nigra pars reticulata than in the subthalamic nucleus.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Apomorphine; Benserazide; Corpus Striatum; Dopamine Agents; Dopamine Agonists; Injections, Intraperitoneal; Levodopa; Male; Motor Activity; Oxidopamine; Quinolinic Acid; Rats; Rats, Wistar; Substantia Nigra; Thalamic Nuclei | 1998 |
Effect of systemic L-DOPA administration on extracellular kynurenate levels in the rat striatum.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Astrocytes; Dopamine; Dose-Response Relationship, Drug; Down-Regulation; Extracellular Space; Kynurenic Acid; Levodopa; Male; Neostriatum; Neurons; Neurotoxins; Oxidopamine; Parkinson Disease; Quinolinic Acid; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Receptors, N-Methyl-D-Aspartate; Receptors, Nicotinic; Substantia Nigra | 2002 |
Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in Parkinsonian monkeys.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Female; Kynurenic Acid; Kynurenine 3-Monooxygenase; Levodopa; Macaca fascicularis; Mixed Function Oxygenases; Motor Activity; Parkinsonian Disorders; Quinolinic Acid; Sulfonamides; Thiazoles; Time Factors | 2005 |
Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Female; Kynurenic Acid; Kynurenine; Kynurenine 3-Monooxygenase; Levodopa; Macaca fascicularis; Motor Activity; Parkinsonian Disorders; Quinolinic Acid; Sulfonamides; Thiazoles; Time Factors | 2008 |
l-dopa-induced dyskinesias in unilateral 6-hydroxydopamine-lesioned rats are not modified by excitotoxic lesion of the entopeduncular nucleus and substantia nigra pars reticulata.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Entopeduncular Nucleus; Levodopa; Male; Movement; Neurons; Oxidopamine; Quinolinic Acid; Rats; Rats, Sprague-Dawley; Substantia Nigra | 2013 |
A rat model of striatonigral degeneration generated by simultaneous injection of 6-hydroxydopamine into the medial forebrain bundle and quinolinic acid into the striatum.
Topics: Animals; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Glucose; Injections, Intraperitoneal; Levodopa; Male; Medial Forebrain Bundle; Oxidopamine; Parkinson Disease; Positron-Emission Tomography; Quinolinic Acid; Rats; Rats, Wistar; Striatonigral Degeneration; Touch | 2014 |
L-dopa response pattern in a rat model of mild striatonigral degeneration.
Topics: Animals; Behavior, Animal; Corpus Striatum; Denervation; Disease Models, Animal; Levodopa; Motor Activity; Multiple System Atrophy; Quinolinic Acid; Rats; Striatonigral Degeneration | 2019 |